文献速递心力衰竭与心肌病

重新评估心力衰竭药物开发中替代终点的作用

Reassessing the Role of Surrogate End Points in Drug Development for Heart Failure.
PubMed 文献 · Circulation · 2018-01-01

综述基于2016年心血管临床试验论坛的讨论,重新审视心衰II期试验中替代终点的角色。文章指出II期结果与III期试验日益不一致,急性心衰和射血分数保留心衰仍缺乏确切验证的疗法。作者分析了常用替代终点的挑战与经验教训,并提出优化心衰药物开发效率的建议。

要点

  • II期心衰试验结果与III期试验日益不一致,需重新审视替代终点。
  • 急性心衰和HFpEF仍无确切验证的疗法。
  • 应优化II期试验设计以提高药物开发效率。

核心结论

  • II期心衰试验的初步结果常令人鼓舞,但III期结果日益令人失望,提示需重新评估替代终点的作用。

主要发现

  • 时间趋势分析提示早期与III期试验终点间的不一致率增加。
  • 急性心衰或射血分数保留心衰仍无确切验证的疗法。

临床怎么用

  • 应审慎重新评估II期心衰试验的目的、设计与执行,尤其关注常用替代终点。
  • 优化心衰药物开发效率需考虑多种方法。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

With few notable exceptions, drug development for heart failure (HF) has become progressively more challenging, and there remain no definitively proven therapies for patients with acute HF or HF with preserved ejection fraction. Inspection of temporal trends suggests an increasing rate of disagreement between early-phase and phase III trial end points. Preliminary results from phase II HF trials are frequently promising, but increasingly followed by disappointing phase III results. Given this potential disconnect, it is reasonable to carefully re-evaluate the purpose, design, and execution of phase II HF trials, with particular attention directed toward the surrogate end points commonly used by these studies. In this review, we offer a critical reappraisal of the role of phase II HF trials and surrogate end points, highlighting challenges in their use and interpretation, lessons learned from past experiences, and specific strengths and weaknesses of various surrogate outcomes. We conclude by proposing a series of approaches that should be considered for the goal of optimizing the efficiency of HF drug development. This review is based on discussions between scientists, clinical trialists, industry and government sponsors, and regulators that took place at the Cardiovascular Clinical Trialists Forum in Washington, DC, on December 2, 2016.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Greene SJ, Mentz RJ, Fiuzat M, et al. Reassessing the Role of Surrogate End Points in Drug Development for Heart Failure. Circulation. 2018. PMID: 30354535. doi:10.1161/CIRCULATIONAHA.118.034668

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。